Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
British Journal of Cancer|March 23, 2018
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinomaD H Palmer, Y T Ma, M Peck-Radosavljevic, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 28, 2017
Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical managementP A Sutton, P V Jithesh, R P Jones, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|April 23, 2024
Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient managementT M Gilbert, L Randle, M Quinn, et al.Oncology Reports|June 26, 2008
A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient settingS A Hussain, D H Palmer, D E Swinson, et al.Journal of Proteomics|March 9, 2018
Proteomic profiling of rectal cancer reveals acid ceramidase is implicated in radiation responseD L Bowden, P A Sutton, M A Wall, et al.British Journal of Cancer|January 11, 2007
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancerS A Hussain, R Ganesan, G Reynolds, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|December 15, 2016
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK AuditJ King, D H Palmer, P Johnson, et al.The Journal of Clinical Endocrinology and Metabolism|November 19, 2015
Effect of Valvular Surgery in Carcinoid Heart Disease: An Observational Cohort StudyN C Edwards, M Yuan, O Nolan, et al.ESMO Open|June 25, 2026
Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trialA Lamarca, D H Palmer, H S Wasan, et al.British Journal of Cancer|March 11, 2018
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapyN O Elander, K Aughton, P Ghaneh, et al.Pageof 4